Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

PSMA-617

 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

DipeptidesHeterocyclic Compounds, 1-Ring

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2017
Highly Cited
2017
German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients
177Lu-labeled PSMA-617 is a promising new therapeutic agent for radioligand therapy (RLT) of patients with metastatic castration… Expand
  • table 1
  • table 2
  • table 3
  • figure 1
  • figure 2
Is this relevant?
Highly Cited
2017
Highly Cited
2017
44Sc-PSMA-617 for radiotheragnostics in tandem with 177Lu-PSMA-617—preclinical investigations in comparison with 68Ga-PSMA-11 and 68Ga-PSMA-617
BackgroundThe targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic purposes… Expand
  • figure 1
  • table 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Targeted alpha therapy of mCRPC: Dosimetry estimate of 213Bismuth-PSMA-617
PurposePSMA-617 is a small molecule targeting the prostate-specific membrane antigen (PSMA). In this work, we estimate the… Expand
  • table 1
  • figure 1
  • table 2
  • figure 2
  • figure 3
Is this relevant?
2017
2017
Delayed response after repeated 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration resistant prostate cancer
PurposeRadioligand therapy (RLT) using Lutetium-177 labeled PSMA-617 (Lu-PSMA) ligand is a new therapeutic option for salvage… Expand
  • table 1
  • figure 1
  • figure 3
  • figure 2
Is this relevant?
Highly Cited
2016
Highly Cited
2016
PSMA-Targeted Radionuclide Therapy of Metastatic Castration-Resistant Prostate Cancer with 177Lu-Labeled PSMA-617
Prostate-specific membrane antigen (PSMA) is an excellent target for radionuclide therapy of metastasized castration-resistant… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
Highly Cited
2016
Highly Cited
2016
F-18 labelled PSMA-1007: biodistribution, radiation dosimetry and histopathological validation of tumor lesions in prostate cancer patients
PurposeThe prostate-specific membrane antigen (PSMA) targeted positron-emitting-tomography (PET) tracer 68Ga-PSMA-11 shows great… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Is this relevant?
Review
2016
Review
2016
The Rise of PSMA Ligands for Diagnosis and Therapy of Prostate Cancer
The prostate-specific membrane antigen (PSMA) has received increased consideration during the past few years as an excellent… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2016
2016
18F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617
The biochemical and radiological responses to radionuclide therapy with Lu-PSMA-617 targeting prostate-specific membrane antigen… Expand
Is this relevant?
Highly Cited
2015
Highly Cited
2015
The Theranostic PSMA Ligand PSMA-617 in the Diagnosis of Prostate Cancer by PET/CT: Biodistribution in Humans, Radiation Dosimetry, and First Evaluation of Tumor Lesions
PET imaging with the prostate-specific membrane antigen (PSMA)–targeted radioligand 68Ga-PSMA-11 is regarded as a significant… Expand
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
Highly Cited
2015
Highly Cited
2015
Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer
Despite many advances in the past years, the treatment of metastatic prostate cancer still remains challenging. In recent years… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE